Regulators of carcinogenesis: Emerging roles beyond their primary functions

Cancer Letters

Volumn 357, Issue 1, 2015, Pages 75-82

  Jia, Lin Tao ^a   Zhang, Rui ^a   Shen, Lan ^a   Yang, An Gang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Cyclin dependent kinase; Epidermal growth factor receptor; Metabolic enzyme

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLINE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR; MICRORNA; PROTEIN TYROSINE KINASE INHIBITOR;

APOPTOSIS; AUTOPHAGY; CANCER CELL; CARCINOGENESIS; CELL CYCLE REGULATION; CELL NUCLEUS; CELL ORGANELLE; CELL RENEWAL; CELL SURVIVAL; CELLULAR DISTRIBUTION; CYTOPLASM; CYTOSOL; DNA SYNTHESIS; DRUG RESISTANCE; ENZYME ACTIVITY; NECROPTOSIS; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; SHORT SURVEY; SIGNAL TRANSDUCTION; STEM CELL; HUMAN; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY;

APOPTOSIS; CARCINOGENESIS; CYCLIN-DEPENDENT KINASES; HUMANS; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84920374040     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.11.048     Document Type: Review

References (118)

1. Giancotti F.G. Deregulation of cell signaling in cancer. FEBS Lett 2014, 588:2558-2570.
2. Umar A., Dunn B.K., Greenwald P. Future directions in cancer prevention. Nat. Rev. Cancer 2012, 12:835-848.
3. Adam J., Yang M., Soga T., Pollard P.J. Rare insights into cancer biology. Oncogene 2014, 33:2547-2556.
4. Ladomery M. Aberrant alternative splicing is another hallmark of cancer. Int. J. Cell Biol 2013, 2013:463786.
5. Pesch B., Bruning T., Johnen G., Casjens S., Bonberg N., Taeger D., et al. Biomarker research with prospective study designs for the early detection of cancer. Biochim. Biophys. Acta 1844, 2014:874-883.
6. Fernald K., Kurokawa M. Evading apoptosis in cancer. Trends Cell Biol 2013, 23:620-633.
7. Masoudi-Nejad A., Asgari Y. Metabolic cancer biology: structural-based analysis of cancer as a metabolic disease, new sights and opportunities for disease treatment. Semin. Cancer Biol 2014.
8. Panaretto B.A. Aspects of growth factor signal transduction in the cell cytoplasm. J. Cell Sci 1994, 107(Pt 4):747-752.
9. Williams G.H., Stoeber K. The cell cycle and cancer. J. Pathol 2012, 226:352-364.
10. Atanasova M., Whitty A. Understanding cytokine and growth factor receptor activation mechanisms. Crit. Rev. Biochem. Mol. Biol 2012, 47:502-530.
11. Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst 2005, 97:643-655.
12. Pao W., Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat. Rev. Cancer 2010, 10:760-774.
13. Bunn P.A., Franklin W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin. Oncol 2002, 29:38-44.
14. Chong C.R., Janne P.A. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat. Med 2013, 19:1389-1400.
15. Scaltriti M., Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin. Cancer Res 2006, 12:5268-5272.
16. Huang T.H., Huo L., Wang Y.N., Xia W., Wei Y., Chang S.S., et al. Epidermal growth factor receptor potentiates MCM7-mediated DNA replication through tyrosine phosphorylation of Lyn kinase in human cancers. Cancer Cell 2013, 23:796-810.
17. Krol J., Loedige I., Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet 2010, 11:597-610.
18. Yates L.A., Norbury C.J., Gilbert R.J. The long and short of microRNA. Cell 2013, 153:516-519.
19. Shen J., Xia W., Khotskaya Y.B., Huo L., Nakanishi K., Lim S.O., et al. EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature 2013, 497:383-387.
20. Guo J.Y., Xia B., White E. Autophagy-mediated tumor promotion. Cell 2013, 155:1216-1219.
21. Mizushima N., Komatsu M. Autophagy: renovation of cells and tissues. Cell 2011, 147:728-741.
22. Wei Y., Zou Z., Becker N., Anderson M., Sumpter R., Xiao G., et al. EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. Cell 2013, 154:1269-1284.
23. Fan Q.W., Cheng C.K., Gustafson W.C., Charron E., Zipper P., Wong R.A., et al. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell 2013, 24:438-449.
24. Fafalios A., Ma J., Tan X., Stoops J., Luo J., Defrances M.C., et al. A hepatocyte growth factor receptor (Met)-insulin receptor hybrid governs hepatic glucose metabolism. Nat. Med 2011, 17:1577-1584.
25. Singh D., Chan J.M., Zoppoli P., Niola F., Sullivan R., Castano A., et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012, 337:1231-1235.
26. Snuderl M., Batista A., Kirkpatrick N.D., Ruiz de Almodovar C., Riedemann L., Walsh E.C., et al. Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell 2013, 152:1065-1076.
27. Hizli A.A., Chi Y., Swanger J., Carter J.H., Liao Y., Welcker M., et al. Phosphorylation of eukaryotic elongation factor 2 (eEF2) by cyclin A-cyclin-dependent kinase 2 regulates its inhibition by eEF2 kinase. Mol. Cell. Biol 2013, 33:596-604.
28. Pefani D.E., Latusek R., Pires I., Grawenda A.M., Yee K.S., Hamilton G., et al. RASSF1A-LATS1 signalling stabilizes replication forks by restricting CDK2-mediated phosphorylation of BRCA2. Nat. Cell Biol 2014, 16:962-971. 961-968.
29. Yang H.C., Chuang J.Y., Jeng W.Y., Liu C.I., Wang A.H., Lu P.J., et al. Pin1-mediated Sp1 phosphorylation by CDK1 increases Sp1 stability and decreases its DNA-binding activity during mitosis. Nucleic Acids Res 2014.
30. Yalcin A., Clem B.F., Imbert-Fernandez Y., Ozcan S.C., Peker S., O'Neal J., et al. 6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27. Cell Death Dis 2014, 5:e1337.
31. Warfel N.A., Dolloff N.G., Dicker D.T., Malysz J., El-Deiry W.S. CDK1 stabilizes HIF-1alpha via direct phosphorylation of Ser668 to promote tumor growth. Cell Cycle 2013, 12:3689-3701.
32. Liu C.C., Gopalakrishnan V., Poon L.F., Yan T., Li S. Cdk1 regulates the temporal recruitment of telomerase and Cdc13-Stn1-Ten1 complex for telomere replication. Mol. Cell. Biol 2014, 34:57-70.
33. Yang S., Zhang L., Liu M., Chong R., Ding S.J., Chen Y., et al. CDK1 phosphorylation of YAP promotes mitotic defects and cell motility and is essential for neoplastic transformation. Cancer Res 2013, 73:6722-6733.
34. Kotak S., Busso C., Gonczy P. NuMA phosphorylation by CDK1 couples mitotic progression with cortical dynein function. EMBO J. 2013, 32:2517-2529.
35. Estey M.P., Di Ciano-Oliveira C., Froese C.D., Fung K.Y., Steels J.D., Litchfield D.W., et al. Mitotic regulation of SEPT9 protein by cyclin-dependent kinase 1 (Cdk1) and Pin1 protein is important for the completion of cytokinesis. J. Biol. Chem 2013, 288:30075-30086.
36. Lu M., Breyssens H., Salter V., Zhong S., Hu Y., Baer C., et al. Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP. Cancer Cell 2013, 23:618-633.
37. Cho Y.Y., Tang F., Yao K., Lu C., Zhu F., Zheng D., et al. Cyclin-dependent kinase-3-mediated c-Jun phosphorylation at Ser63 and Ser73 enhances cell transformation. Cancer Res 2009, 69:272-281.
38. Zheng D., Cho Y.Y., Lau A.T., Zhang J., Ma W.Y., Bode A.M., et al. Cyclin-dependent kinase 3-mediated activating transcription factor 1 phosphorylation enhances cell transformation. Cancer Res 2008, 68:7650-7660.
39. Firestein R., Bass A.J., Kim S.Y., Dunn I.F., Silver S.J., Guney I., et al. CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature 2008, 455:547-551.
40. Morris E.J., Ji J.Y., Yang F., Di Stefano L., Herr A., Moon N.S., et al. E2F1 represses beta-catenin transcription and is antagonized by both pRB and CDK8. Nature 2008, 455:552-556.
41. Casimiro M.C., Crosariol M., Loro E., Ertel A., Yu Z., Dampier W., et al. ChIP sequencing of cyclin D1 reveals a transcriptional role in chromosomal instability in mice. J. Clin. Invest 2012, 122:833-843.
42. Lee Y., Dominy J.E., Choi Y.J., Jurczak M., Tolliday N., Camporez J.P., et al. Cyclin D1-Cdk4 controls glucose metabolism independently of cell cycle progression. Nature 2014, 510:547-551.
43. Anders L., Ke N., Hydbring P., Choi Y.J., Widlund H.R., Chick J.M., et al. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell 2011, 20:620-634.
44. Handschick K., Beuerlein K., Jurida L., Bartkuhn M., Muller H., Soelch J., et al. Cyclin-dependent kinase 6 is a chromatin-bound cofactor for NF-kappaB-dependent gene expression. Mol. Cell 2014, 53:193-208.
45. Wan C., Hou S., Ni R., Lv L., Ding Z., Huang X., et al. MIF4G domain containing protein regulates cell cycle and hepatic carcinogenesis by antagonizing CDK2-dependent p27 stability. Oncogene 2013.
46. Duong M.T., Akli S., Macalou S., Biernacka A., Debeb B.G., Yi M., et al. Hbo1 is a cyclin E/CDK2 substrate that enriches breast cancer stem-like cells. Cancer Res 2013, 73:5556-5568.
47. Kwiatkowski N., Zhang T., Rahl P.B., Abraham B.J., Reddy J., Ficarro S.B., et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature 2014, 511:616-620.
48. Wang Y., Liu F., Mao F., Hang Q., Huang X., He S., et al. Interaction with cyclin H/cyclin-dependent kinase 7 (CCNH/CDK7) stabilizes C-terminal binding protein 2 (CtBP2) and promotes cancer cell migration. J. Biol. Chem 2013, 288:9028-9034.
49. Yokoyama H., Gruss O.J., Rybina S., Caudron M., Schelder M., Wilm M., et al. Cdk11 is a RanGTP-dependent microtubule stabilization factor that regulates spindle assembly rate. J. Cell Biol 2008, 180:867-875.
50. Shi J., Feng Y., Goulet A.C., Vaillancourt R.R., Sachs N.A., Hershey J.W., et al. The p34cdc2-related cyclin-dependent kinase 11 interacts with the p47 subunit of eukaryotic initiation factor 3 during apoptosis. J. Biol. Chem 2003, 278:5062-5071.
51. Mbogning J., Nagy S., Page V., Schwer B., Shuman S., Fisher R.P., et al. The PAF complex and Prf1/Rtf1 delineate distinct Cdk9-dependent pathways regulating transcription elongation in fission yeast. PLoS Genet 2013, 9:e1004029.
52. Shchebet A., Karpiuk O., Kremmer E., Eick D., Johnsen S.A. Phosphorylation by cyclin-dependent kinase-9 controls ubiquitin-conjugating enzyme-2A function. Cell Cycle 2012, 11:2122-2127.
53. Filippova N., Yang X., King P., Nabors L.B. Phosphoregulation of the RNA-binding protein Hu antigen R (HuR) by Cdk5 affects centrosome function. J. Biol. Chem 2012, 287:32277-32287.
54. Hsu F.N., Chen M.C., Chiang M.C., Lin E., Lee Y.T., Huang P.H., et al. Regulation of androgen receptor and prostate cancer growth by cyclin-dependent kinase 5. J. Biol. Chem 2011, 286:33141-33149.
55. Banks A.S., McAllister F.E., Camporez J.P., Zushin P.J., Jurczak M.J., Laznik-Bogoslavski D., et al. An ERK/Cdk5 axis controls the diabetogenic actions of PPARgamma. Nature 2014.
56. Kang M.J., Chung J., Ryoo H.D. CDK5 and MEKK1 mediate pro-apoptotic signalling following endoplasmic reticulum stress in an autosomal dominant retinitis pigmentosa model. Nat. Cell Biol 2012, 14:409-415.
57. Bertoli C., Skotheim J.M., de Bruin R.A. Control of cell cycle transcription during G1 and S phases. Nat. Rev. Mol. Cell Biol 2013, 14:518-528.
58. Lim S., Kaldis P. Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development 2013, 140:3079-3093.
59. Lavrik I., Golks A., Krammer P.H. Death receptor signaling. J. Cell Sci 2005, 118:265-267.
60. Chalah A., Khosravi-Far R. The mitochondrial death pathway. Adv. Exp. Med. Biol 2008, 615:25-45.
61. Peter M.E. Programmed cell death: apoptosis meets necrosis. Nature 2011, 471:310-312.
62. Kung G., Konstantinidis K., Kitsis R.N. Programmed necrosis, not apoptosis, in the heart. Circ. Res 2011, 108:1017-1036.
63. Brint E., O'Callaghan G., Houston A. Life in the Fas lane: differential outcomes of Fas signaling. Cell. Mol. Life Sci 2013, 70:4085-4099.
64. Kaufmann T., Strasser A., Jost P.J. Fas death receptor signalling: roles of Bid and XIAP. Cell Death Differ 2012, 19:42-50.
65. Barbero S., Mielgo A., Torres V., Teitz T., Shields D.J., Mikolon D., et al. Caspase-8 association with the focal adhesion complex promotes tumor cell migration and metastasis. Cancer Res 2009, 69:3755-3763.
66. Hardwick J.M., Soane L. Multiple functions of BCL-2 family proteins. Cold Spring Harb. Perspect. Biol 2013, 5.
67. Moldoveanu T., Follis A.V., Kriwacki R.W., Green D.R. Many players in BCL-2 family affairs. Trends Biochem. Sci 2014, 39:101-111.
68. Shamas-Din A., Kale J., Leber B., Andrews D.W. Mechanisms of action of Bcl-2 family proteins. Cold Spring Harb. Perspect. Biol 2013, 5:a008714.
69. Maejima Y., Kyoi S., Zhai P., Liu T., Li H., Ivessa A., et al. Mst1 inhibits autophagy by promoting the interaction between Beclin1 and Bcl-2. Nat. Med 2013, 19:1478-1488.
70. Maryanovich M., Oberkovitz G., Niv H., Vorobiyov L., Zaltsman Y., Brenner O., et al. The ATM-BID pathway regulates quiescence and survival of haematopoietic stem cells. Nat. Cell Biol 2012, 14:535-541.
71. Papadopoulos K. Targeting the Bcl-2 family in cancer therapy. Semin. Oncol 2006, 33:449-456.
72. Lopez J., Meier P. To fight or die - inhibitor of apoptosis proteins at the crossroad of innate immunity and death. Curr. Opin. Cell Biol 2010, 22:872-881.
73. Mufti A.R., Burstein E., Duckett C.S. XIAP: cell death regulation meets copper homeostasis. Arch. Biochem. Biophys 2007, 463:168-174.
74. Hornle M., Peters N., Thayaparasingham B., Vorsmann H., Kashkar H., Kulms D. Caspase-3 cleaves XIAP in a positive feedback loop to sensitize melanoma cells to TRAIL-induced apoptosis. Oncogene 2011, 30:575-587.
75. Gu L., Zhu N., Zhang H., Durden D.L., Feng Y., Zhou M. Regulation of XIAP translation and induction by MDM2 following irradiation. Cancer Cell 2009, 15:363-375.
76. Huang X., Wu Z., Mei Y., Wu M. XIAP inhibits autophagy via XIAP-Mdm2-p53 signalling. EMBO J. 2013, 32:2204-2216.
77. Cairns R.A., Harris I.S., Mak T.W. Regulation of cancer cell metabolism. Nat. Rev. Cancer 2011, 11:85-95.
78. Blum R., Jacob-Hirsch J., Amariglio N., Rechavi G., Kloog Y. Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. Cancer Res 2005, 65:999-1006.
79. Chesney J., Telang S. Regulation of glycolytic and mitochondrial metabolism by ras. Curr. Pharm. Biotechnol 2013, 14:251-260.
80. Koppenol W.H., Bounds P.L., Dang C.V. Otto Warburg's contributions to current concepts of cancer metabolism. Nat. Rev. Cancer 2011, 11:325-337.
81. Coller H.A. Is cancer a metabolic disease?. Am. J. Pathol 2014, 184:4-17.
82. Guo C., Liu S., Sun M.Z. Novel insight into the role of GAPDH playing in tumor. Clin. Transl. Oncol 2013, 15:167-172.
83. Iqbal M.A., Gupta V., Gopinath P., Mazurek S., Bamezai R.N. Pyruvate kinase M2 and cancer: an updated assessment. FEBS Lett 2014, 588:2685-2692.
84. Ma I., Allan A.L. The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev 2011, 7:292-306.
85. Gao X., Wang H., Yang J.J., Liu X., Liu Z.R. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol. Cell 2012, 45:598-609.
86. Yang W., Xia Y., Hawke D., Li X., Liang J., Xing D., et al. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 2012, 150:685-696.
87. Luo W., Hu H., Chang R., Zhong J., Knabel M., O'Meally R., et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 2011, 145:732-744.
88. Cairns R.A., Mak T.W. Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer Discov 2013, 3:730-741.
89. Lu C., Ward P.S., Kapoor G.S., Rohle D., Turcan S., Abdel-Wahab O., et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012, 483:474-478.
90. Saha S.K., Parachoniak C.A., Ghanta K.S., Fitamant J., Ross K.N., Najem M.S., et al. Mutant IDH inhibits HNF-4alpha to block hepatocyte differentiation and promote biliary cancer. Nature 2014.
91. Zheng L., Roeder R.G., Luo Y. S phase activation of the histone H2B promoter by OCA-S, a coactivator complex that contains GAPDH as a key component. Cell 2003, 114:255-266.
92. Colell A., Ricci J.E., Tait S., Milasta S., Maurer U., Bouchier-Hayes L., et al. GAPDH and autophagy preserve survival after apoptotic cytochrome c release in the absence of caspase activation. Cell 2007, 129:983-997.
93. Tarze A., Deniaud A., Le Bras M., Maillier E., Molle D., Larochette N., et al. GAPDH, a novel regulator of the pro-apoptotic mitochondrial membrane permeabilization. Oncogene 2007, 26:2606-2620.
94. Nicholls C., Pinto A.R., Li H., Li L., Wang L., Simpson R., et al. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) induces cancer cell senescence by interacting with telomerase RNA component. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:13308-13313.
95. Du W., Jiang P., Mancuso A., Stonestrom A., Brewer M.D., Minn A.J., et al. TAp73 enhances the pentose phosphate pathway and supports cell proliferation. Nat. Cell Biol 2013, 15:991-1000.
96. Jiang P., Du W., Mancuso A., Wellen K.E., Yang X. Reciprocal regulation of p53 and malic enzymes modulates metabolism and senescence. Nature 2013, 493:689-693.
97. Casaletto J.B., McClatchey A.I. Spatial regulation of receptor tyrosine kinases in development and cancer. Nat. Rev. Cancer 2012, 12:387-400.
98. Catalano V., Turdo A., Di Franco S., Dieli F., Todaro M., Stassi G. Tumor and its microenvironment: a synergistic interplay. Semin. Cancer Biol 2013, 23:522-532.
99. Hollander M.C., Blumenthal G.M., Dennis P.A. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat. Rev. Cancer 2011, 11:289-301.
100. Hopkins B.D., Fine B., Steinbach N., Dendy M., Rapp Z., Shaw J., et al. A secreted PTEN phosphatase that enters cells to alter signaling and survival. Science 2013, 341:399-402.
101. Lo H.W. Nuclear mode of the EGFR signaling network: biology, prognostic value, and therapeutic implications. Discov. Med 2010, 10:44-51.
102. Lee S.M., Kim J.H., Cho E.J., Youn H.D. A nucleocytoplasmic malate dehydrogenase regulates p53 transcriptional activity in response to metabolic stress. Cell Death Differ 2009, 16:738-748.
103. Stefan C.J., Manford A.G., Emr S.D. ER-PM connections: sites of information transfer and inter-organelle communication. Curr. Opin. Cell Biol 2013, 25:434-442.
104. Akl H., Vervloessem T., Kiviluoto S., Bittremieux M., Parys J.B., De Smedt H., et al. A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum. Biochim. Biophys. Acta 2014, 1843:2240-2252.
105. Cao X., Zhu H., Ali-Osman F., Lo H.W. EGFR and EGFRvIII undergo stress- and EGFR kinase inhibitor-induced mitochondrial translocalization: a potential mechanism of EGFR-driven antagonism of apoptosis. Mol. Cancer 2011, 10:26.
106. Wickner W., Schekman R. Protein translocation across biological membranes. Science 2005, 310:1452-1456.
107. Studer R.A., Dessailly B.H., Orengo C.A. Residue mutations and their impact on protein structure and function: detecting beneficial and pathogenic changes. Biochem. J. 2013, 449:581-594.
108. Schwartz A.L. Cell biology of intracellular protein trafficking. Annu. Rev. Immunol 1990, 8:195-229.
109. Light S., Elofsson A. The impact of splicing on protein domain architecture. Curr. Opin. Struct. Biol 2013, 23:451-458.
110. Biamonti G., Catillo M., Pignataro D., Montecucco A., Ghigna C. The alternative splicing side of cancer. Semin. Cell Dev. Biol 2014, 32C:30-36.
111. Bunting S.F., Nussenzweig A. End-joining, translocations and cancer. Nat. Rev. Cancer 2013, 13:443-454.
112. Ng K.P., Hillmer A.M., Chuah C.T., Juan W.C., Ko T.K., Teo A.S., et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat. Med 2012, 18:521-528.
113. Butturini A., Arlinghaus R.B., Gale R.P. BCR/ABL and leukemia. Leuk. Res 1996, 20:523-529.
114. Seidah N.G., Chretien M. Eukaryotic protein processing: endoproteolysis of precursor proteins. Curr. Opin. Biotechnol 1997, 8:602-607.
115. Kantari C., Walczak H. Caspase-8 and bid: caught in the act between death receptors and mitochondria. Biochim. Biophys. Acta 2011, 1813:558-563.
116. Wirawan E., Vande Walle L., Kersse K., Cornelis S., Claerhout S., Vanoverberghe I., et al. Caspase-mediated cleavage of Beclin-1 inactivates Beclin-1-induced autophagy and enhances apoptosis by promoting the release of proapoptotic factors from mitochondria. Cell Death Dis 2010, 1:e18.
117. Yuan B.Z., Chapman J., Reynolds S.H. Proteasome inhibitors induce apoptosis in human lung cancer cells through a positive feedback mechanism and the subsequent Mcl-1 protein cleavage. Oncogene 2009, 28:3775-3786.
118. Jeffery C.J. Multifunctional proteins: examples of gene sharing. Ann. Med 2003, 35:28-35.